Keynote Speaker

Michael A. Curran, PhD
Associate Professor, Dept. of Immunology
Scientific Director, ORBIT Platform
The University of Texas MD Anderson Cancer Center
Department of Immunology, Division of Basic Sciences

Keynote Speaker

Stephan A. Grupp, MD, PhD
Director of the Cancer Immunotherapy Program
Director of Translational Research for the Center for
Childhood Cancer Research at CHOP
Medical Director of the Stem Cell Laboratory

Children’s Hospital of Philadelphia

Cancer Progress 2020 Panels:

  • Paradigm-shifting platforms I, IO: Taking IO to the next Level

  • Paradigm-shifting platforms II, Non-IO: Targeting Better, Targeting the Intractable

  • Investing into Oncology: Who, What and Where?

  • Vaccines: From Paleo to Neo, Cancer Vaccines in the New Age of IO

  • Next Wave of Diagnostics, Including Precision IO: Early and Smarter, the Better to Cure

  • Inflecting Value in Early Stage Biotech ( in an Increasingly Cost Conscious Environment): Linking Proof of Relevance to Pricing & Reimbursement

And Introducing: Advanced Therapeutics – ½ day session

  • Antigen/platform pairings (“Forget Wine and Cheese…Get this Right and Your Valuation Takes Flight”)

  • State of the union for off-the-shelf (“In an ‘Allo or Bust’ Market, What’s Rising to the Top of the Shelf?”)

  • What are investors and partners looking for today (“How to Stand Out/Inflect Value in a Frothy Vat of Cells”)

The 31st Annual Cancer Progress Conference

By Cello Health BioConsulting, Previously Defined Health

Inspiring Cancer Progress through engaged stakeholder dialogue

Since 1989, Cancer Progress is the only oncology conference that invites a discussion of scientific progresswithin the context of development, regulatory, clinical, commercial and investment perspectives in two daysof interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation andgenerous networking throughout the meeting during breaks, luncheons, reception and dinner combine tomake this a highly impactful conference.

Our 31st Annual Meeting on May 5-6, 2020 will provide an unsurpassed learning experience for participantsin quality of information, coverage of issues, and value of professional contacts. The quality of the speakingfaculty is a major contributor to the popularity and value of this conference.

Thank You to our 2019 Sponsors and Supporters


Convene at 32 Old Slip
32 Old Slip, New York, NY 10005 | 1.888.730.7307


“I truly enjoyed the conference. I told several colleagues and friends that this has been one of the best conferences I have ever attended.”

Christoph Lengauer, Chief Scientific Officer

Blueprint Medicines

“What an unbelievable 2-day event that was. The intimate atmosphere (I made great new contacts) and dynamic (sometimes “dynamic tension”) interaction between panel members was fantastic. I kept great notes and have already shared the very enthusiastic feedback & takeaways with my management team.”

Armand Girard, Vice President, Corporate Development


“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa


“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company